Jack Cush is a journalist for RheumNow, specializing in rheumatology and related topics. With a focus on providing up-to-date information to healthcare professionals and patients, Jack covers a wide range of subjects including drug approvals, research findings, treatment guidelines, and emerging trends in the field of rheumatology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jack Cush's coverage is heavily focused on healthcare and pharmaceutical topics, specifically in the realm of rheumatology and osteoarthritis. Given that 72% of his articles cite data, it is likely that he would be interested in pitches from experts who can provide evidence-based insights or share new research findings related to these specific medical conditions.
He may also be open to receiving pitches about scientific advancements, particularly those related to drug-induced disorders and non-pharmacological management strategies for musculoskeletal conditions like arthritis.
As Jack does not have a specified geographic focus, sources with international expertise or insights into global trends in rheumatology and medical research could appeal to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
reatments for Dupuytren's contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited.
A real-world cohort study suggests that psoriatic arthritis filing to respond to TNF inhibitors (TNFi), may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Medscape has published a survey overview of US Medical Students and their impressions and experience, why they applied, what they think of their education and how prepared are they for the USMLE (boards) and residency.
Iberdomide, a cereblon modulator, that promotes degradation of transcription factors Ikaros and Aiolos has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).
The NEJM reports what should be obvious to rheumatologists: that older adults with severe hip osteoarthritis should opt for total hip replacement (THR) over conservative exercise measures as THR yields a clinically important improvement in pain and function.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
A randomized trial of 140 adults with chronic low back pain (CLBP) demonstrated that virtual yoga instruction resulted in significant improvements in CLBP patients compared to the wait-list control group.
A EULAR taskforce has evaluated the effect of lifestyle behaviours in rheumatic and musculoskeletal diseases (RMDs) and concluding that there is moderate evidence for a small benefit for certain dietary components, but overall, high-level evidence regarding dietary exposures on outcomes in RMDs is lacking.
(833) 317-6278 
